Journal of American Association for Pediatric Ophthalmology and Strabismus
EditorialBevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?
References (26)
- et al.
Retinopathy of prematurity in the time of bevacizumab: Incorporating the BEAT-ROP results into clinical practice
Ophthalmology
(2011) Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease
Surv Ophthalmol
(2011)- et al.
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy
Ophthalmology
(2006) - et al.
Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema
J AAPOS
(2009) - et al.
Pharmacokinetics of intravitreal bevacizumab (Avastin)
Ophthalmology
(2007) Extrapolating anti-vascular endothelial growth factor therapy into pediatric ophthalmology: Promise and concern
J AAPOS
(2009)- et al.
Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor
Ophthalmology
(2009) - et al.
Comparing protein VEGF inhibitors: In vitro biological studies
Biochem Biophys Res Commun
(2011) - et al.
Efficacy of intravitreal bevacizumab for stage 3 retinopathy of prematurity
N Engl J Med
(2011) - Darlow BA, Ells AL, Gilbert CE, Gole GA, Quinn GE. Are we there yet? Bevacizumab therapy for retinopathy of...
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
N Engl J Med
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: Ranibizumab and bevacizumab
Eye (Lond)
Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema
Retina
Cited by (51)
Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti–Vascular Endothelial Growth Factor
2021, OphthalmologyCitation Excerpt :These studies should be interpreted with caution, because treatment methods generally were not randomized and sicker infants tended to be treated with anti-VEGF agents instead of laser therapy.45 Finally, ideal dosing of bevacizumab for ROP has yet to be established.46–48 Wallace et al49 recently demonstrated good results with 0.004 mg, considerably less than the 0.625 mg used in the Bevacizumab Eliminates the Angiogenic Threat of ROP Study.
Intravitreal bevacizumab versus ranibizumab: Effects on the vessels of the fellow non-treated eye
2019, Journal of Current OphthalmologyPathophysiology, screening and treatment of ROP: A multi-disciplinary perspective
2018, Progress in Retinal and Eye ResearchAdvances in understanding and management of retinopathy of prematurity
2017, Survey of OphthalmologyCitation Excerpt :One dose of bevacizumab, an anti-VEGF agent, led to persistent avascular retina and recurrent disease,85,160 even 2.5 years later.2,10,64,67,83,149,160–163,166–168 The direct comparison of anti-VEGF treatment between premature infant and adult eyes also suggests that ¼ the dose in vitreous in the infant eye would still be much less diluted in the many fold smaller infant blood volume compared to the adult.17,66 VEGF is important to kidney, brain, and lung development, as well as to retinal health.60